Skip to main content

Royalty Pharma Sub-Manager, LLC

13F filer · CIK 0002081668
Reported Aug 21, 2026
Net buyer this quarter
13F portfolio value$242MU.S. long equity reported on 13F
Positions41 new · 1 closed
Net flow last quarter+$15.6MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 21, 20264 positions
CYTKCytokinetics Inc$83.5M34.52%0.79%Not reportedQ4 2025
ZBIOZenas BioPharma, Inc.$60.6M25.05%3.77%Not reportedQ4 2025
KLRAKailera Therapeutics, Inc.$54.1M22.36%1.89%NewQ2 2026
BHVNBiohaven Ltd.$43.7M18.06%1.94%Not reportedQ4 2025
Q1 2026Reported Aug 21, 20264 positions
CYTKCytokinetics Inc$64.6M37.40%0.80%Not reportedQ4 2025
ZBIOZenas BioPharma, Inc.$46.7M27.02%3.83%+89.1%Q4 2025
BCRXBiocryst Pharmaceuticals Inc$36.6M21.19%1.51%Not reportedQ4 2025
BHVNBiohaven Ltd.$24.8M14.38%1.95%Not reportedQ4 2025
Q4 2025Reported Aug 21, 20264 positions
CYTKCytokinetics Inc$62.3M36.36%0.80%NewQ4 2025
ZBIOZenas BioPharma, Inc.$45.9M26.77%2.32%NewQ4 2025
BHVNBiohaven Ltd.$33.2M19.35%2.21%NewQ4 2025
BCRXBiocryst Pharmaceuticals Inc$30M17.51%1.81%NewQ4 2025
Premium opens every quarter this fund has filed
SpoorBase

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.